D2 receptor occupancy of olanzapine pamoate depot using positron emission tomography: An open-label study in patients with schizophrenia

Neuropsychopharmacology

Volumn 33, Issue 2, 2008, Pages 298-304

  Mamo, David ^a,b   Kapur, Shitij ^a,b   Keshavan, Matcheri ^c   Laruelle, Marc ^d,f   Taylor, Cindy C ^e   Kothare, Prajakti A ^e   Barsoum, Penny ^a   McDonnell, David ^e  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d New York Presbyterian Hospital Columbia University Medical Center   (United States)

^e ELI LILLY AND COMPANY   (United States)

^f GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Depot; Olanzapine; PET; Pharmacokinetics; Receptor occupancy; Schizophrenia

Indexed keywords

BENZATROPINE MESILATE; DIAZEPAM; DOPAMINE 2 RECEPTOR; NEUROLEPTIC AGENT; OLANZAPINE; OLANZAPINE PAMOATE; RACLOPRIDE C 11; UNCLASSIFIED DRUG; BENZODIAZEPINE DERIVATIVE;

ADULT; AKATHISIA; ANXIETY DISORDER; ARTICLE; BRIEF PSYCHIATRIC RATING SCALE; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIZZINESS; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SUBSTITUTION; DRUG TOLERABILITY; FEMALE; GRANULOMA; HUMAN; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; INSOMNIA; MALE; MENTAL PATIENT; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; ORTHOSTATIC BLOOD PRESSURE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PSYCHOSIS; QT PROLONGATION; RECEPTOR OCCUPANCY; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; STEADY STATE; SUPPLEMENTATION; TREATMENT DURATION; WEIGHT GAIN; BLOOD; DRUG EFFECT; METABOLISM; METHODOLOGY; SCINTISCANNING; TIME;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; FEMALE; HUMANS; MALE; POSITRON-EMISSION TOMOGRAPHY; RECEPTORS, DOPAMINE D2; SCHIZOPHRENIA; TIME FACTORS;

EID: 36949008116     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1301409     Document Type: Article

References (19)

1. Dewey SL, Smith GS, Logan J, Brodie JD, Simkowitz P, MacGregor RR et al (1993). Effects of central cholinergic blockade on striatal dopamine release measured with positron emission tomography in normal human subjects. Proc Natl Acad Sci USA 90: 11816-11820.
2. Dewey SL, Smith GS, Logan J, Brodie JD, Yu DW, Ferrieri RA et al (1992). GABAergic inhibition of endogenous dopamine release measured in vivo with 11C-raclopride and positron emission tomography. J Neurosci 12: 3773-3780.
3. Farde L, Hall H, Ehrin E, Sedvall G (1986). Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET. Science 231: 258-261.
4. Gefvert O, Eriksson B, Persson P, Helldin L, Bjorner A, Mannaert E et al (2005). Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta) in patients with schizophrenia. Int J Neuropsychopharmacol 8: 27-36.
5. Guy W (1976). ECDEU Assessment Manual for Psychopharmacology revised edition. US Department of Health, Education and Welfare: Bethesda, MD.
6. Kane JM, Eerdekens M, Lindenmayer JP, Keith SJ, Lesem M, Karcher K (2003). Long-acting injectable Risperidone: efficacy and satey of the first long-acting atypical antipsychotic. Am J Psychiatry 160: 1125-1132.
7. Kapur S, Zipursky R, Jones C, Remington G, Houle S (2000). Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 157: 514-520.
8. Kapur S, Zipursky RB, Jones C, Remington GJ, Wilson AA, DaSilva J et al (1996). The D2 receptor occupancy profile of loxapine determined using PET. Neuropsychopharmacol 15: 562-566.
9. 2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am J Psychiatry 155: 921-928.
10. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO et al (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353: 1209-1223.
11. Mamo D, Sedman E, Tillner J, Sellers EM, Romach MK, Kapur S (2004). EMD 281014, a specific and potent 5HT2 antagonist in humans: a dose-finding PET study. Psychopharmacol 175: 382-388.
12. Nordström AL, Farde L, Wiesel FA, Forslund K, Pauli S, Halldin C et al (1993). Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol Psychiatry 33: 227-235.
13. Overall JE (1972). The Brief Psychiatric Rating Scale in Psychopharmacology Research, Psychometric Laboratory Reports, No. 29. University of Texas: Galveston.
14. Perkins DO (2002). Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry 63: 1121-1128.
15. Perry PJ, Lund BC, Sanger T, Beasley C (2001). Olanzapine plasma concentrations and clinical response: acute phase results of the North American olanzapine trial. J Clin Psychopharmacol 21: 14-20.
16. 2 receptor occupancy for long-acting injectable rsiperidone. Am J Psychiatry 163: 396-401.
17. Studholme C, Hill DL, Hawkes DJ (1997). Automated three-dimensional registration of magnetic resonance and positron emission tomography brain images by multiresolution optimization of voxel similarity measures. Med Phys 24: 25-35.
18. Tauscher J, Jones C, Remington G, Zipursky RB, Kapur S (2002). Significant dissociation of brain and plasma kinetics with antipsychotics. Mol Psychiatry 7: 317-321.
19. Volkow ND, Fowler JS, Wang GJ, Dewey SL, Schlyer D, MacGregor R et al (1993). Reproducibility of repeated measures of carbon-11-raclopride binding in the human brain. J Nucl Med 34: 609-613 (correction, 34(5):838).